735 related articles for article (PubMed ID: 22781947)
21. [Clinical significance of abnormal protein bands in multiple myeloma treated with bortezomib-based induction regimen and autologous stem cell transplantation].
Wang HH; Li J; Liu JR; Zheng D; Gu JL; Yan MS; Zou WY; Xu DR
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):327-31. PubMed ID: 23668206
[TBL] [Abstract][Full Text] [Related]
22. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K
Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093
[TBL] [Abstract][Full Text] [Related]
23. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA
Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Harousseau JL; Attal M; Leleu X; Troncy J; Pegourie B; Stoppa AM; Hulin C; Benboubker L; Fuzibet JG; Renaud M; Moreau P; Avet-Loiseau H
Haematologica; 2006 Nov; 91(11):1498-505. PubMed ID: 17043025
[TBL] [Abstract][Full Text] [Related]
25. Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
Gao W; Geng C; Zhang L; Li Y; Chen W; Wang C
Hematology; 2013 Nov; 18(6):341-7. PubMed ID: 23510553
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
27. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
[TBL] [Abstract][Full Text] [Related]
28. [Retrospective analysis on therapeutic effect of autologous hematopoietic stem cell transplantation in multiple myeloma patients].
Wang J; Fu CC; Wu DP; Sun AN; Xue SL; Xin X; Hu XH; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Han Y; Ma X; He GS; Chang WR; Chen SN
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):114-8. PubMed ID: 23648347
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
31. [Retrospective analysis of 71 cases of multiple myeloma].
Yang P; Zhang WJ; Jing HM; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1573-6. PubMed ID: 20030950
[TBL] [Abstract][Full Text] [Related]
32. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
33. Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
Chim CS; Liu H; Lie AK; Chan EY; Ho S; Wong M; Kwong YL
Hematol Oncol; 2014 Dec; 32(4):205-11. PubMed ID: 24473998
[TBL] [Abstract][Full Text] [Related]
34. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
[TBL] [Abstract][Full Text] [Related]
35. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
Liang Z; Ren H; Cen X; Li Y; Wang L; Ou J; Dong Y; Yin Y; Wang W; Liu W; Wang Q; Qiu Z; Wang M; Xu W; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):225-30. PubMed ID: 24666489
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Jagannath S; Durie BG; Wolf J; Camacho E; Irwin D; Lutzky J; McKinley M; Gabayan E; Mazumder A; Schenkein D; Crowley J
Br J Haematol; 2005 Jun; 129(6):776-83. PubMed ID: 15953004
[TBL] [Abstract][Full Text] [Related]
37. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
Lee SE; Yoon JH; Shin SH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Min CK
Ann Hematol; 2014 Apr; 93(4):627-34. PubMed ID: 24085241
[TBL] [Abstract][Full Text] [Related]
38. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang L; Ran X; Wang B; Sheng Z; Liu L
Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367
[TBL] [Abstract][Full Text] [Related]
39. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
40. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
